Mineralocorticoid receptor antagonist indication and underuse in high‐risk post‐myocardial infarction patients

Abstract

This article refers to 'Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial' by M. Schou et al., published in this issue on pages 130-139.